279 related articles for article (PubMed ID: 18429007)
1. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
2. Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines.
Begum NM; Nakashiro K; Kawamata H; Uchida D; Shintani S; Ikawa Y; Sato M; Hamakawa H
Int J Oncol; 2002 Mar; 20(3):599-605. PubMed ID: 11836575
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent.
Husvik C; Bryne M; Halstensen TS
Eur J Oral Sci; 2009 Oct; 117(5):528-35. PubMed ID: 19758248
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Johnson FM; Yang P; Newman RA; Donato NJ
J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661
[TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
Kwak YE; Jeon NK; Kim J; Lee EJ
Ann N Y Acad Sci; 2007 Jan; 1095():99-112. PubMed ID: 17404023
[TBL] [Abstract][Full Text] [Related]
7. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
Lanza-Jacoby S; Burd R; Rosato FE; McGuire K; Little J; Nougbilly N; Miller S
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6161-9. PubMed ID: 17062693
[TBL] [Abstract][Full Text] [Related]
8. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism.
Lee EJ; Whang JH; Jeon NK; Kim J
Ann N Y Acad Sci; 2007 Jan; 1095():113-28. PubMed ID: 17404024
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
Tencer L; Burgermeister E; Ebert MP; Liscovitch M
Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Akita Y; Kozaki K; Nakagawa A; Saito T; Ito S; Tamada Y; Fujiwara S; Nishikawa N; Uchida K; Yoshikawa K; Noguchi T; Miyaishi O; Shimozato K; Saga S; Matsumoto Y
Br J Dermatol; 2004 Aug; 151(2):472-80. PubMed ID: 15327557
[TBL] [Abstract][Full Text] [Related]
11. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.
Sheu JJ; Hua CH; Wan L; Lin YJ; Lai MT; Tseng HC; Jinawath N; Tsai MH; Chang NW; Lin CF; Lin CC; Hsieh LJ; Wang TL; Shih IeM; Tsai FJ
Cancer Res; 2009 Mar; 69(6):2568-76. PubMed ID: 19276369
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
Nystrom ML; McCulloch D; Weinreb PH; Violette SM; Speight PM; Marshall JF; Hart IR; Thomas GJ
Cancer Res; 2006 Nov; 66(22):10833-42. PubMed ID: 17108119
[TBL] [Abstract][Full Text] [Related]
14. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2007 Nov; 18(5):1281-90. PubMed ID: 17914586
[TBL] [Abstract][Full Text] [Related]
16. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR.
Harris G; Ghazallah RA; Nascene D; Wuertz B; Ondrey FG
Otolaryngol Head Neck Surg; 2005 Nov; 133(5):695-701. PubMed ID: 16274795
[TBL] [Abstract][Full Text] [Related]
17. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
20. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
